ATR-IN-29

Cat. No.:	HY-153729
CAS No.:	2761193-67-1
Molecular Formula:	$C_{19}H_{22}N_8O$
Molecular Weight:	378.43
Target:	ATM/ATR
Pathway:	Cell Cycle/DNA Damage; PI3K/Akt/mTOR
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	ATR-IN-29 is a potent and orally active ATR kinase inhibitor with an IC_{50} value of 1 nM. ATR-IN-29 shows antiproliferative activity[1].
IC_{50} & Target	ATR 1 nM (IC_{50})
In Vitro	ATR-IN-29 (compound 1) (4 days) shows antiproliferative activity with IC_{50}s of 156.70, 38.81, 22.48, 181.60, 19.02 nM for A549, HCC1806, HCT116, OVCAR-3, NCI-H460 cells, respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	ATR-IN-29 (10 mg/kg; p.o.; once) shows good pharmacokinetic parameters with $t_{1/2}$ of 1.64 h, C_{max} of 9343 ng/mL, AUC_{0-t} of 98507 ng·h/mL, AUC_{0-inf} of 98517 ng·h/mL in CD-1 (ICR) mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sui Xiong Cai, et al. Substituted imidazo[1,5-b]pyridazine compounds as kinase inhibitors and use thereof. WO2022135560A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA